Empowered Funds LLC Has $12.07 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Empowered Funds LLC reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 52.8% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 15,618 shares of the biopharmaceutical company’s stock after selling 17,442 shares during the quarter. Empowered Funds LLC’s holdings in Regeneron Pharmaceuticals were worth $12,067,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. WPG Advisers LLC raised its holdings in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the period. SHP Wealth Management bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $26,000. Titan Wealth CI Ltd bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $29,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $31,000. Finally, Birchwood Financial Partners Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $32,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on REGN shares. Canaccord Genuity Group cut their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. Truist Financial cut their price target on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Finally, TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $787.88.

Regeneron Pharmaceuticals Stock Up 0.0%

REGN stock opened at $695.42 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The company has a market cap of $73.52 billion, a PE ratio of 16.94, a price-to-earnings-growth ratio of 27.77 and a beta of 0.24. The business’s 50-day simple moving average is $638.74 and its 200 day simple moving average is $711.76.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same quarter in the prior year, the firm posted $8.22 EPS. The company’s revenue for the quarter was up 19.0% on a year-over-year basis. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 2.06 earnings per share for the current year.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Potentially solid quarterly results: Investors are looking for continued growth from Dupixent, Eylea HD and Libtayo, along with updates on buybacks and Regeneron’s development pipeline. The prior quarter showed strong momentum, with revenue rising 19% year over year and EPS exceeding analyst expectations. Regeneron To Report Earnings Tomorrow
• Positive Sentiment: Partnered Arcalyst momentum: Kiniksa Pharmaceuticals exceeded second-quarter expectations, supported by sales of Arcalyst, which is partnered with Regeneron. The update may reinforce confidence in the commercial performance and royalty contribution of the collaboration, although the impact on REGN is indirect. Kiniksa Tops Q2 Estimates on Regeneron-Partnered Arcalyst
• Neutral Sentiment: Earnings are the next major catalyst: Regeneron is scheduled to report before the market opens Thursday. Investors will focus on product sales, full-year guidance, pipeline commentary and management’s response to the recent clinical setback. Regeneron to Announce Earnings on Thursday
• Negative Sentiment: Failed melanoma trial and litigation overhang: Multiple law firms announced or promoted securities class actions alleging that Regeneron and executives misled investors about the Phase 3 Fianlimab-Libtayo trial, including its protocol changes and clinical differentiation. The trial failure reportedly caused a sharp selloff and an approximately $11 billion loss in market value. The lawsuits themselves may not create an immediate cash liability, but they add reputational, legal and pipeline risk. Investors have until September 14, 2026, to seek lead-plaintiff status. Regeneron Investor Alert

Insider Activity

In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.